The GlaxoSmithKline PLC line shows up 178 times in the congressional disclosure record between 2012 and 2025, filed by 47 members: 141 purchases against 35 sales. On balance the chamber has been net buyers, and the purchases sit up 33.6% against the latest close.
*Purchases only, weighted by the midpoint of each disclosed dollar band and marked to the latest close. Filings report a range, never a share count, so this follows the stock rather than anyone's position size.
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2015-04-27 | K. Michael Conaway | SELL | $1K–$15K | $46.85 | $51.10 2026-10-26 | -9.1% exit |
| 2015-04-08 | Brian Babin | BUY | $1K–$15K | $47.41 | $51.10 2026-10-26 | +7.8% |
| 2015-03-27 | Kenny Marchant | SELL | $1K–$15K | $47.02 | $51.10 2026-10-26 | -8.7% exit |
| 2015-03-27 | Kenny Marchant | BUY | $1K–$15K | $47.02 | $51.10 2026-10-26 | +8.7% |
| 2015-03-12 | Kenny Marchant | SELL | $1K–$15K | $46.37 | $51.10 2026-10-26 | -10.2% exit |
| 2015-03-12 | Kenny Marchant | BUY | $1K–$15K | $46.37 | $51.10 2026-10-26 | +10.2% |
| 2015-03-05 | Kenny Marchant | SELL | $1K–$15K | $47.60 | $51.10 2026-10-26 | -7.3% exit |
| 2015-03-05 | Kenny Marchant | BUY | $1K–$15K | $47.60 | $51.10 2026-10-26 | +7.3% |
| 2015-03-02 | Fred Upton | BUY | $1K–$15K | $47.93 | $51.10 2026-10-26 | +6.6% |
| 2015-02-06 | Fred Upton | BUY | $1K–$15K | $46.00 | $51.10 2026-10-26 | +11.1% |
| 2015-02-06 | Mike Kelly | BUY | $1K–$15K | $46.00 | $51.10 2026-10-26 | +11.1% |
| 2015-01-29 | Tom Price | BUY | $1K–$15K | $45.16 | $51.10 2026-10-26 | +13.2% |
| 2015-01-23 | James B. Renacci | BUY | $1K–$15K | $45.01 | $51.10 2026-10-26 | +13.5% |
| 2014-06-13 | RICHARD M BURR | BUY | $1K–$15K | $54.50 | $51.10 2026-10-26 | -6.2% |
| 2014-03-25 | Fred Upton | BUY | $1K–$15K | $53.89 | $51.10 2026-10-26 | -5.2% |
| 2013-01-15 | THOMAS R CARPER | SELL | $1K–$15K | $43.94 | $51.10 2026-10-26 | -16.3% exit |
| 2013-01-15 | THOMAS R CARPER | BUY | $1K–$15K | $43.94 | $51.10 2026-10-26 | +16.3% |
| 2012-11-29 | THOMAS R CARPER | SELL | $1K–$15K | $43.40 | $51.10 2026-10-26 | -17.7% exit |
| Mike Kelly | BUY | $1K–$15K | — | — | — | |
| Mike Kelly | BUY | $1K–$15K | — | — | — | |
| Kurt Schrader | BUY | $1K–$15K | — | — | — | |
| Mike Kelly | BUY | $1K–$15K | — | — | — | |
| Kurt Schrader | BUY | $1K–$15K | — | — | — | |
| Kenny Marchant | BUY | $1K–$15K | — | — | — | |
| Kurt Schrader | BUY | $1K–$15K | — | — | — | |
| Anna Paulina Luna | SELL | $1K–$15K | — | — | — exit | |
| Anna Paulina Luna | BUY | $1K–$15K | — | — | — | |
| Kurt Schrader | BUY | $1K–$15K | — | — | — |
Buys are marked to the latest close and treated as open. A sell tagged rt closes an earlier disclosed buy in the same name. exit shows how the stock moved after the member sold.
47 members of the U.S. House and Senate have disclosed GlaxoSmithKline PLC transactions under the STOCK Act — 141 purchases and 35 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a GSK purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Notional-weighted, lawmakers' disclosed GSK buys are up 33.6% versus the latest close of $51.10. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded GSK and how it performed.